REQUIP RLS Post Marketing Surveillance

• Status: Completed
• Trial end date: 2009-11-30
• Target enrollment: 0
• Participant gender: All

Summary

post-marketing surveillance to monitor safety and efficacy of ropinirole during using of treatment for RLS

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Ropinirole

Criteria

Inclusion Criteria:

• Subjects diagnosed with RLS by the investigator

• Subjects who the investigator believes that they can and will comply with the requirements of the protocol

• To be contactable over the phone

• To follow the administration regimen.

• A male or female aged 18 years and more at the time of the first prescription.

• Subjects with no experience of RLS treatment using ropinirole

Exclusion Criteria:

Considering the nature of this non-interventional PMS study, there is no strict exclusion criteria set up. GSK Korea encourage the doctors participating this study to enrol the subjects prescribed with Ropinirole following the locally approved Prescribing Information (Appendix ) The following criteria should be checked at the time of study entry.

• Subjects with hypersensitivity to ropinirole and any excipients

• Female who is during the period of the pregnancy or who are lactating